A Follow-up Study of Asymptomatic Infections and Diagnosed Patients With Covid-19 in Shanghai
NCT ID: NCT05387304
Last Updated: 2022-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
250000 participants
OBSERVATIONAL
2022-03-29
2032-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiological Study on Asymptomatic Infections and Mild Illness With Covid-19 in Shanghai
NCT05375786
A Retrospective Study in Patients With Mild to Moderate COVID-19
NCT05374772
An Observational Study in Patients With Mild to Moderate COVID-19
NCT05366244
Early Identification and Severity Prediction of Acute Respiratory Infectious Disease
NCT04955756
Respiratory Virome Diversity and Baseline Immunity in Healthy Individuals in Shanghai
NCT06641856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 infections
SARS-Cov-2 RNA postive
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* informed consent signed
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guang Ning, Ph D
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Erzhen Chen, Ph D
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCAM2022-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.